×

ANTI-ERYTHROPOIETIN ANTIBODIES

  • US 20130295113A1
  • Filed: 05/07/2013
  • Published: 11/07/2013
  • Est. Priority Date: 05/07/2012
  • Status: Active Grant
First Claim
Patent Images

1. An isolated antibody or fragment of an antibody, wherein the antibody or the fragment specifically binds to human erythropoietin and comprises:

  • a. a VH CDR1 having an amino acid sequence identical to or comprising 0, 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    36;

    b. a VH CDR2 having an amino acid sequence identical to or comprising 0, 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    37;

    c. a VH CDR3 having an amino acid sequence identical to or comprising 0, 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    38;

    d. a VL CDR1 having an amino acid sequence identical to or comprising 0, 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    6;

    e. a VL CDR2 having an amino acid sequence identical to or comprising 0, 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    7; and

    f. a VL CDR3 having an amino acid sequence identical to or comprising 0, 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    8;

    org. a VH CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    42;

    h. a VH CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    43;

    i. a VH CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    44;

    j. a VL CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    12;

    k. a VL CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    13; and

    l. a VL CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    14;

    orm. a VH CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    48;

    n. a VH CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    49;

    o. a VH CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    50;

    p. a VL CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    18;

    q. a VL CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    19; and

    r. a VL CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    20;

    ors. a VH CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    54;

    t. a VH CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    55;

    u. a VH CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    56;

    v. a VL CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    24;

    w. a VL CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    25; and

    x. a VL CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    26;

    ory. a VH CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    60;

    z. a VH CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    61;

    aa. a VH CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    62;

    bb. a VL CDR1 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    30;

    cc. a VL CDR2 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    31; and

    dd. a VL CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions relative to SEQ ID NO;

    32.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×